Long-Term Outcomes of Extent of Revascularization in Complex High Risk and Indicated Patients Undergoing Impella-Protected Percutaneous Coronary Intervention: Report from the Roma-Verona Registry
暂无分享,去创建一个
A. M. Leone | F. Burzotta | C. Trani | G. Niccoli | I. Porto | F. Crea | D. D’Amario | C. Aurigemma | F. Ribichini | G. Pesarini | L. Paraggio | G. Russo | A. Piccoli | L. Previ | D. Verdirosi | A. Leone | Leonardo Previ
[1] M. Borggrefe,et al. Comparison of peri and post-procedural complications in patients undergoing revascularisation of coronary artery multivessel disease by coronary artery bypass grafting or protected percutaneous coronary intervention with the Impella 2.5 device , 2019, European heart journal. Acute cardiovascular care.
[2] F. Burzotta,et al. Angio-Guidewire-Ultrasound (AGU) Guidance for Femoral Access in Procedures Requiring Large Sheaths. , 2019, The Journal of invasive cardiology.
[3] F. Burzotta,et al. Hemodynamics and its predictors during Impella-protected PCI in high risk patients with reduced ejection fraction. , 2019, International journal of cardiology.
[4] G. Dangas,et al. Complete Revascularization During Primary Percutaneous Coronary Intervention Reduces Death and Myocardial Infarction in Patients With Multivessel Disease: Meta-Analysis and Meta-Regression of Randomized Trials. , 2018, JACC. Cardiovascular interventions.
[5] F. Burzotta,et al. Impella: pumps overview and access site management. , 2018, Minerva cardioangiologica.
[6] F. Ribichini,et al. Impella-protected PCI: the clinical results achieved so far. , 2018, Minerva cardioangiologica.
[7] F. Burzotta,et al. Definitions and clinical impact of revascularization completeness. , 2018, Minerva cardioangiologica.
[8] D. Westermann,et al. Indication and short-term clinical outcomes of high-risk percutaneous coronary intervention with microaxial Impella® pump: results from the German Impella® registry , 2018, Clinical Research in Cardiology.
[9] C. Grines,et al. Real‐world supported unprotected left main percutaneous coronary intervention with impella device; data from the USpella registry , 2017, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[10] I. Palacios,et al. Treatment of Higher-Risk Patients With an Indication for Revascularization: Evolution Within the Field of Contemporary Percutaneous Coronary Intervention , 2016, Circulation.
[11] F. Burzotta,et al. Impella ventricular support in clinical practice: Collaborative viewpoint from a European expert user group. , 2015, International journal of cardiology.
[12] Victor Mor-Avi,et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.
[13] Samin K. Sharma,et al. Patients with 3-vessel coronary artery disease and impaired ventricular function undergoing PCI with Impella 2.5 hemodynamic support have improved 90-day outcomes compared to intra-aortic balloon pump: a sub-study of the PROTECT II trial. , 2015, Journal of interventional cardiology.
[14] Victor Mor-Avi,et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[15] T. Sundt,et al. Surgical Ineligibility and Mortality Among Patients With Unprotected Left Main or Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention , 2014, Circulation.
[16] F. Burzotta,et al. Percutaneous management of vascular access in transfemoral transcatheter aortic valve implantation. , 2014, World journal of cardiology.
[17] Samin K. Sharma,et al. Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial). , 2014, The American journal of cardiology.
[18] D. Perera,et al. Prognostic utility of BCIS myocardial jeopardy score for classification of coronary disease burden and completeness of revascularization. , 2013, The American journal of cardiology.
[19] Jeroen J. Bax,et al. Third universal definition of myocardial infarction , 2013, Nature Reviews Cardiology.
[20] W. O’Neill,et al. Real‐world use of the Impella 2.5 circulatory support system in complex high‐risk percutaneous coronary intervention: The USpella Registry , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[21] I. Palacios,et al. A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary Intervention: The PROTECT II Study , 2012, Circulation.
[22] P. Serruys,et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score. , 2012, Journal of the American College of Cardiology.
[23] Maarten L. Simoons,et al. The third universal definition of myocardial infarction , 2013 .
[24] Laura Mauri,et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.
[25] G. Levine,et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.
[26] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[27] P. Serruys,et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium , 2010, European heart journal.
[28] Volkmar Falk,et al. Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .
[29] D. Wagner,et al. Supported high-risk percutaneous coronary intervention with the Impella 2.5 device the Europella registry. , 2009, Journal of the American College of Cardiology.
[30] R. Stables,et al. The balloon pump-assisted coronary intervention study (BCIS-1): rationale and design. , 2009, American heart journal.
[31] Biswajit Kar,et al. A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): initial U.S. experience. , 2009, JACC. Cardiovascular interventions.
[32] A. M. Leone,et al. Feasibility and long-term safety of elective Impella-assisted high-risk percutaneous coronary intervention: a pilot two-centre study , 2008, Journal of cardiovascular medicine.